| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Rafael Holdings Inc. Class B | CPI-613 (devimistat) + hydroxychloroquine | Relapsed or Refractory Myelodysplastic Syndrome (MDS) | Phase 2 | Trial Completed | Intravenous and oral | Hematology |
| Rafael Holdings Inc. Class B | CPI-613 (devimistat) + mFOLFIRINOX | Locally advanced pancreatic cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Rallybio Corporation | RLYB212 | Fetal and neonatal alloimmune thrombocytopenia (FNAIT) | Phase 2 | Trial Discontinued | Intravenous | Hematology |
| Rapport Therapeutics Inc. | RAP-219 | Bipolar mania | Phase 2a | Trial Planned | Oral | Psychiatric |
| Rapport Therapeutics Inc. | RAP-219 - (FOS) | Focal epilepsy | Phase 2a | Data Released | oral | Neurology |
| Rapport Therapeutics Inc. | RAP-219 - (PET) | Drug-resistant focal epilepsy | Phase 2a | Type Meeting | Intravenous | Neurology |
| RAPT Therapeutics Inc. | RPT904 - (prestIgE) | Food allergy | Phase 2b | IND Clearance | Subcutaneous | Immunology |
| RAPT Therapeutics Inc. | RPT904 - (prestIgE) | Food allergy | Phase 2b | IND Clearance | Subcutaneous | Immunology |